+

PE20081345A1 - Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico - Google Patents

Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico

Info

Publication number
PE20081345A1
PE20081345A1 PE2007001559A PE2007001559A PE20081345A1 PE 20081345 A1 PE20081345 A1 PE 20081345A1 PE 2007001559 A PE2007001559 A PE 2007001559A PE 2007001559 A PE2007001559 A PE 2007001559A PE 20081345 A1 PE20081345 A1 PE 20081345A1
Authority
PE
Peru
Prior art keywords
alkyl
agonists
receptor
nicotinum
compounds containing
Prior art date
Application number
PE2007001559A
Other languages
English (en)
Inventor
Anandan Palani
Dong Xiao
Xianhai Huang
Xiao Chen
Jun Qin
Ying R Huang
Robert G Aslanian
Jing Su
Sylvia J Degrado
Ashwin U Rao
Haiqun Tang
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/600,216 external-priority patent/US7750015B2/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20081345A1 publication Critical patent/PE20081345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE Q ES (a), (b), (c), (d) O (e); L ES (f), (g), (h) O (i); R1 ES H, ALQUILO, ARILALQUILO, ENTRE OTROS; R2 ES H, HALOGENO, HALOALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, ALQUILO SUSTITUIDO CON OH,CICLOALQUILO, ENTRE OTROS; R4 ES H, ALQUILO, HALOALQUILO, ENTRE OTROS; R5 ES H, ALQUILO, OH, HALOALQUILO, ENTRE OTROS; R6 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; Ra Y Rb SON H, ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; Rc ES H, ALQUILO, ALQUILEN-ARILO, C(O)-ALQUILO; Rd ES H, ALQUILO, ALQUILEN-ARILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DEL ACIDO NICOTINICO Y SON UTILES EN EL TRATAMIENTO DEL SINDROME METABOLICO, DISLIPIDEMIAS, ENFERMEDADES CARDIOVASCULARES, ENTRE OTROS
PE2007001559A 2006-11-15 2007-11-12 Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico PE20081345A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,216 US7750015B2 (en) 2005-05-17 2006-11-15 Nitrogen-containing heterocyclic compounds and methods of use thereof
US11/771,538 US7737155B2 (en) 2005-05-17 2007-06-29 Nitrogen-containing heterocyclic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20081345A1 true PE20081345A1 (es) 2008-10-24

Family

ID=39301219

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001559A PE20081345A1 (es) 2006-11-15 2007-11-12 Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico

Country Status (17)

Country Link
US (3) US7737155B2 (es)
EP (1) EP2059519B1 (es)
JP (1) JP5020331B2 (es)
KR (1) KR20090083461A (es)
CN (1) CN101589041A (es)
AR (1) AR063800A1 (es)
AU (1) AU2007319940A1 (es)
CA (1) CA2669670A1 (es)
CL (1) CL2007003265A1 (es)
CO (1) CO6220970A2 (es)
EC (1) ECSP099335A (es)
MX (1) MX2009005217A (es)
NO (1) NO20092286L (es)
PE (1) PE20081345A1 (es)
RU (1) RU2009122245A (es)
TW (1) TW200825090A (es)
WO (1) WO2008060476A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610133A2 (pt) * 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR059056A1 (es) * 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
JP2011520969A (ja) 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
CN106377501A (zh) * 2008-08-01 2017-02-08 医药公司 药物组合物和用于稳定药物组合物的方法
WO2010014727A1 (en) * 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for producing low impurity concentrations of the same
WO2010036600A1 (en) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Pharmaceutical compositions of atorvastatin
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
BR112016015236B1 (pt) 2013-12-30 2023-11-14 Array Biopharma Inc. Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN104193687B (zh) * 2014-07-01 2017-09-26 上海天慈国际药业有限公司 一种治疗肺动脉高压药物的制备方法
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
AR127404A1 (es) * 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
JP2024546107A (ja) 2021-12-09 2024-12-17 デシフェラ・ファーマシューティカルズ，エルエルシー Ｒａｆキナーゼ阻害剤及びその使用方法
CN117069662A (zh) * 2023-10-17 2023-11-17 峰成医药科技(天津)有限公司 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2826580A (en) * 1958-03-11 Derivatives of y
US3139432A (en) * 1963-06-24 1964-06-30 Mead Johnson & Co Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4215216A (en) * 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
CA1258454A (en) 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
IT1159765B (it) 1982-09-28 1987-03-04 Zanussi A Spa Industrie Macchina lavabiancheria di tipo modulare
GB8410485D0 (en) * 1984-04-24 1984-05-31 Waddington John Plc Label cutting
DD263891A3 (de) 1986-12-23 1989-01-18 Dresden Arzneimittel Verbessertes verfahren zur herstellung von 2,4,6,8-tetrahydroxy-yrimido[5,4-d] pyrimidin und seinen salzen
DD265760A3 (de) 1987-05-25 1989-03-15 Dresden Arzneimittel Verfahren zur herstellung von 2,4,6,8-tetrachlorpyrimido-[5,4-d]pyrimidin
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5519001A (en) 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
PL321136A1 (en) 1994-11-07 1997-11-24 Pfizer Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
EP0836620A1 (en) 1995-01-31 1998-04-22 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5668990A (en) 1995-03-30 1997-09-16 Pitney Bowes Inc. Apparatus and method for generating 100% United States Postal Service bar coded lists
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CA2274594C (en) 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
US6100259A (en) 1997-01-21 2000-08-08 Smithkline Beecham Corporation Cannabinoid receptor modulators
US6251947B1 (en) 1997-02-04 2001-06-26 Board Of Trustees Of The University Of Arkansas Fungicidal carboxamides
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
KR100586349B1 (ko) 1997-02-21 2006-06-08 바이엘 악티엔게젤샤프트 아릴술폰아미드 및 그의 유사체, 및 신경 변성 질병 치료에있어서 그의 용도
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
US5948777A (en) 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
WO1998047505A1 (fr) 1997-04-23 1998-10-29 Banyu Pharmaceutical Co., Ltd. Antagoniste de recepteur de neuropeptide y
TR199902803T2 (xx) 1997-05-14 2000-07-21 Atherogenics, Inc. VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
AU8127998A (en) 1997-07-11 1999-02-08 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
AU3464599A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives
ATE269846T1 (de) 1998-04-29 2004-07-15 Ortho Mcneil Pharm Inc N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
WO2000007617A1 (en) 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040137563A9 (en) * 1998-10-13 2004-07-15 Ruoping Chen Endogenous and non-endogenous versions of human G protein-coupled receptors
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
CA2350714A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
EP1140184B1 (en) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
JP2003519087A (ja) 1999-03-19 2003-06-17 クノール・ゲー・エム・ベー・ハー 摂食障害を治療する方法
PT1183245E (pt) 1999-04-22 2007-07-12 Lundbeck & Co As H Antagonistas selectivos de npy (y5)
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
CA2373035A1 (en) 1999-05-05 2000-11-16 Scott Dax 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
US6291476B1 (en) 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
JP2003503486A (ja) 1999-06-30 2003-01-28 シナプティック・ファーマスーティカル・コーポレーション 選択的ｎｐｙ（ｙ５）アンタゴニスト
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
NZ516782A (en) 1999-07-28 2004-12-24 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
US6677382B1 (en) 1999-09-23 2004-01-13 Pharmacia Corporation Substituted N,N-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6924313B1 (en) 1999-09-23 2005-08-02 Pfizer Inc. Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6583183B2 (en) 1999-09-23 2003-06-24 Pharmacia Corporation Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
AU7738000A (en) 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
OA12049A (en) 1999-09-30 2006-05-02 Neurogen Corp Amino substituted pyrazoloÄ1,5,-aÜ-1,5-pyrimidinesand pyrazoloÄ1,5,-aÜ-1,3,5-triazines.
DZ3192A1 (fr) 1999-10-13 2001-04-19 Pfizer Prod Inc Dérivés de diaryl ether utilises comme inhibiteursdu recaptage de monoamines.
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
DE60022386T2 (de) 1999-12-16 2006-06-22 Schering Corp. Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
US6482862B1 (en) 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001062738A1 (fr) 2000-02-22 2001-08-30 Banyu Pharmaceutical Co., Ltd. Composes a base d'imidazoline
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
MXPA02008535A (es) * 2000-03-06 2002-12-13 Warner Lambert Co Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa.
IL150986A0 (en) 2000-03-14 2003-02-12 Actelion Pharmaceuticals Ltd 1,2,3,4,- tetrahydroisoquinoline derivatives
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
WO2001085173A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine npy antagonists
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
PT1289955E (pt) 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
CA2384041A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
EP1366030A2 (en) 2000-07-06 2003-12-03 Neurogen Corporation Melanin concentrating hormone receptor ligands
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
AU2001283938A1 (en) 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
AU8395501A (en) 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
CZ2003390A3 (en) 2000-08-15 2004-03-17 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
US20040006120A1 (en) 2000-08-21 2004-01-08 Yates Stephen L Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
MXPA03002263A (es) 2000-09-14 2003-06-24 Schering Corp Antagonistas de receptor de neuropeptido y y5 de urea sustituidos.
DK1322651T3 (da) * 2000-09-22 2008-06-02 Organon Nv Bicykliske, heteroaromatiske forbindelser
MXPA03003246A (es) 2000-10-16 2003-06-06 Hoffmann La Roche Derivados de indolina y su uso como ligandos del receptor 5-ht2.
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
CN1227237C (zh) 2000-11-20 2005-11-16 比奥维特罗姆股份公司 作为五羟色胺5－ht2受体拮抗剂的哌嗪基吡嗪化合物
NZ525700A (en) 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
JP2004520299A (ja) 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
PL208242B1 (pl) 2000-12-20 2011-04-29 Schering Corp Pochodna 2-azetydynonu, zawierająca ją farmaceutyczna kompozycja i zastosowanie tej pochodnej, oraz farmaceutyczna kompozycja zawierająca kombinację tej pochodnej i zastosowanie takiej kombinacji
PL362379A1 (en) 2000-12-21 2004-10-18 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
JP4226326B2 (ja) 2000-12-21 2009-02-18 シェーリング コーポレイション ヘテロアリール尿素神経ペプチドｙｙ５レセプターアンタゴニスト
DE60112791T2 (de) 2000-12-22 2006-06-08 Schering Corp. Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
AU2002228007B2 (en) 2000-12-27 2007-06-21 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-HT2b and 5-HT2c receptor ligands
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
MXPA03007623A (es) * 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
DE60202270T2 (de) 2001-03-22 2005-05-19 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
DE10134529C2 (de) * 2001-07-16 2003-07-03 Bosch Gmbh Robert Injektor mit hintereinandergeschalteten, nach innen öffnenden Ventilen
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DE60236322D1 (de) * 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2004083587A (ja) * 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
KR100772297B1 (ko) 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JP2006512359A (ja) 2002-12-20 2006-04-13 ファイザー・プロダクツ・インク ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形
ATE461700T1 (de) 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
AU2004259269A1 (en) * 2003-07-18 2005-02-03 Basf Aktiengesellschaft Aryl-condensed 3-arylpyridine compounds and use thereof for controlling pathogenic fungi
BRPI0413363A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
JP2007507481A (ja) 2003-09-30 2007-03-29 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害薬及びその代謝産物
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20050251869A1 (en) * 2004-05-04 2005-11-10 Tian-Quan Cai Animal model for raising HDL-cholesterol with niacin
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
CA2584904A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
CA2595477A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AU2006214286A1 (en) 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) * 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
WO2007021744A1 (en) 2005-08-10 2007-02-22 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
US8691498B2 (en) 2005-09-02 2014-04-08 Arena Pharmaceuticals, Inc. Methods of screening for a compound that reduces atherogenesis
AR059056A1 (es) * 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
AR065996A1 (es) 2007-04-13 2009-07-15 Schering Corp Derivados de pirimidindiona,composiciones farmaceuticas que los conitenen y usos en el tratamiento y/o prevencion de la obesidad, diabetes, dislipidemia entre otras patologias.
AU2009296743A1 (en) * 2008-09-23 2010-04-01 Bach Pharma Inc. Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and NRF2 transcription factors

Also Published As

Publication number Publication date
EP2059519B1 (en) 2013-12-18
CL2007003265A1 (es) 2008-06-06
RU2009122245A (ru) 2010-12-20
US20080019978A1 (en) 2008-01-24
US20110152259A1 (en) 2011-06-23
CA2669670A1 (en) 2008-05-22
JP2010509397A (ja) 2010-03-25
AR063800A1 (es) 2009-02-18
AU2007319940A1 (en) 2008-05-22
CO6220970A2 (es) 2010-11-19
MX2009005217A (es) 2009-07-31
KR20090083461A (ko) 2009-08-03
WO2008060476A2 (en) 2008-05-22
US20100227873A1 (en) 2010-09-09
EP2059519A2 (en) 2009-05-20
US7737155B2 (en) 2010-06-15
JP5020331B2 (ja) 2012-09-05
CN101589041A (zh) 2009-11-25
ECSP099335A (es) 2009-06-30
WO2008060476A3 (en) 2008-12-24
TW200825090A (en) 2008-06-16
NO20092286L (no) 2009-08-13

Similar Documents

Publication Publication Date Title
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20091725A1 (es) Activadores piridazinona de la glucoquinasa
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20110368A1 (es) Moduladores de mif
PE20061099A1 (es) Compuestos de piridil acido acetico como inhibidores de peptidasa
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20090772A1 (es) Derivados de bencimidazol
PE20121045A1 (es) Agonista de gpr119
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20142282A1 (es) Nuevos derivados de aril-quinolina
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载